The Canadian Intellectual Property Office has released a proposed new section of Chapter 17 (Biotechnology and Medicinal Inventions) of its Manual of Patent Office Practice (MOPOP), on the examination of pharmaceutical solid forms such as polymorphs, salts, hydrates, solvates, desolvates and co-crystals.
Consultation on the new MOPOP section is open until August 10, 2018.
Related Publications & Articles
-
Medical device updates: MDEL modernization, Class III & IV licence applications, and MDD performance reports
As we previously reported, Health Canada announced that the Phase II amendments to the Medical Devices Regulations (MDR) regarding medical device establishment licences (MDELs) will come into force De...Read More -
Comparing Supplementary Protection Regimes Between Canada (CSPs) and the EU (SPCs)
Amendments to the Patent Act and enactment of the Certificate of Supplementary Protection Regulations flowing from the Canada-European Union (EU) Comprehensive Economic and Trade Agreement (CETA, see ...Read More -
Health Canada takes action to address generic drug submission review backlog
Health Canada is not currently meeting its performance standards for the review of some generic drug submissions. On September 1, 2026, Health Canada launched a new webpage, Improving how we review ge...Read More
